LLY vs NVO — which stock performed better?

Eli Lilly and Company (LLY) versus Novo Nordisk A/S (NVO), Health Care, on 2026-07-23.

Result

Eli Lilly and Company (LLY) performed better on 2026-07-23. LLY moved 2.270%, NVO moved -1.670%.

Why these two companies

On Tuesday, July 21, 2026, Novo Nordisk filed a federal lawsuit against Eli Lilly accusing it of running deceptive advertising that overstates the effectiveness of its GLP-1 weight-loss drugs compared with Novo's own medicines. The suit escalates the already fierce rivalry between the two dominant makers of GLP-1 obesity and diabetes treatments, giving players a genuine, freshly-litigated reason to compare the two stocks head-to-head.

The research

Eli Lilly makes medicines for diabetes and weight loss, including the well-known Mounjaro and Zepbound treatments, plus a wide range of other drugs for cancer and other conditions. Novo Nordisk is a Danish company that makes Ozempic and Wegovy, some of the most talked-about weight-loss and diabetes medicines in the world. These two companies just became involved in a public legal dispute: Novo Nordisk says Lilly's ads about its weight-loss drugs are misleading, and Lilly says its ads are accurate and plans to fight the claim.

One reason some investors like Eli Lilly right now is that its weight-loss and diabetes drug sales have been growing very quickly in the United States, and the company has a large number of other medicines in development. One reason some investors like Novo Nordisk is that its stock is cheaper relative to its profits than Lilly's, and some believe that makes it a better bargain if the company's newer drugs perform well.

Something worth keeping in mind for Eli Lilly is that its stock price already reflects very high expectations, so any disappointing news can cause a bigger drop than it might for a cheaper stock. Something worth keeping in mind for Novo Nordisk is that it has been losing ground to Lilly in the U.S. weight-loss market, and investors are waiting to see whether its newer drugs can help it catch back up.

Both companies report their next quarterly results in the first week of August 2026, and the new advertising lawsuit between them could keep generating headlines before then, so news about the case itself may move either stock independently of their business performance.